The role of human platelet alloantigens (HPA) in clinical bone marrow allotransplantation was investigated. The leading hypothesis was that HPA alloepitopes act as minor histocompatibility antigens and aggravate graftversus-host disease (GVHD). To exclude the effect of MHC disparity, only HLA identical donor-recipient pairs were entered into the study. The influence of HPA compatibility on overall survival, occurrence of relapses and haematopoietic recovery was also investigated. A total of 223 patients who received a graft from an HLAidentical sibling, genotyped for HPA -1, -2, -3, -4 and -5, were observed over a post-transplant period of 24 months following the protocol recommended by EBMT. The data from patients having received grafts from HPA compatible donors were compared to data from patients having received grafts that were mismatched in HPA allotypes in the GVH direction. Analysis of the incidence of acute and chronic (GVHD), overall survival, relapse incidence, haematopoietic recovery and some other clinical parameters did not reveal any significant difference between the HPA-matched and -mismatched groups of patients, regardless of their age. Our results give no evidence that HPA-1, -2, -3 and -5 alloantigens should be considered minor transplantation antigens in clinical bone marrow transplantation.
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The acceptance of grafted allogeneic haematopoietic tissue is determined by HLA compatibility between the donor and recipient. However, the main complication, graft-versus-host disease (GVHD), can be expected in 10-60% of cases in which the donor and recipient are HLA-identical siblings with identical chromosome no. 6. 1, 2 This immunological risk has been attributed to non-MHC coded alloantigens, termed minor histocompatibility antigens (mHA). 3, 4 There is substantial evidence that mHA are polymorphic peptides derived from proteins or their fragments that are processed within various cell compartments. They are brought to the cell surface during biosynthesis of MHC class I and class II molecules. In vivo responses to mHA are generated if they are recognised by CD4+, MHC class II restricted as well as by CD8+, MHC class I restricted T cells. 5 Some mHA are probably widely distributed, while others may be present only in the haematopoietic tissues or limited to blood cells. 6, 7 Investigations are under way to identify peptides derived from polymorphic molecules that could possibly serve as targets involved in GVHD. [8] [9] [10] Although several human mHAs were identified so far, [11] [12] [13] [14] [15] only the disparity in HA-1 was clinically recognised as a cause of GVHD. 1 The clinical relevance of other mHA remains unclear.
The antigenicity of human platelet alloantigens (HPA) and their presence on different cell types are arguments that prompted us to investigate if HPA molecules could be put on the list of potential mHA and taken into consideration in the selection of bone marrow donors.
Antigens HPA-1, -2, -3, -4 and -5 are epitopes on platelet-specific glycoprotein complexes GPIIb/IIIa, GPIaIIa and GPIbab-V-IX. The molecules GPIIb/IIIa and GPIa-IIa are integrins coded on the 17th, 5th and 10th chromosome. The molecules GPIbab-V-IX, coded on the 17th, 22nd and 3rd chromosome, belong to the leucine-rich repeat glycoprotein family. A single nucleotide substitution in the corresponding glycoprotein genes resulted in two serologically distinguishable epitopes at each HPA locus. The molecular structure of HPA antigens and methods used in detecting allotypic differences within the immunogenetic system HPA have been extensively reviewed elsewhere. [16] [17] [18] [19] Although named 'platelet specific', certain glycoproteins carrying HPA epitopes were also found on other cells. Glycoprotein GPIIIa (CD61) with epitopes HPA-1, -4, -6, -7, -8, -10 and -11 was found on vascular endothelial cells, 20, 21 vascular smooth muscle cells, 22 osteoclasts, 23, 24 human synovial intima, 25 human enterocytes 26 and in cirrhotic liver cells. 27 Glycoprotein GPIba (CD42ba) with HPA-2 alloepitope was found on vascular and tonsilar epithelial cells. 28 Glycoprotein GPIa (CD49b) with HPA-5 and -13 alloepitopes was found on monocytes, B-and T lymphocytes and NK-cells, stem cells, vascular endothelial cells and thymic endothelial cells. [29] [30] [31] Contrary to other glycoproteins, GPIIb (CD 41), carrying the HPA-3 and HPA-9 alloepitopes, was only found on megakaryocytes and platelets. 21 Foreign HPA molecules stimulate the humoral immune response. Blood transfusions and pregnancy are frequently followed by a synthesis of HPA-specific antibodies. Among the best-documented clinical consequences of allosensibilisation are refractoriness to platelet transfusion, posttransfusion thrombocytopenic purpura and neonatal thrombocytopenia. 32 HPA antibodies can also be induced in patients who have undergone kidney transplantation. 33 There is evidence that the fetal antigen HPA -1a can only elicit the production of specific antibodies in an HPA1b/1b mother typed as HLA-DR52 (DRB3*0101). 34 A restriction of humoral response in pregnancy to the antigen HPA-5b by women typed as HLA-DR6 has also been reported. 35 There is limited information on the impact of HPA compatibility in organ and bone marrow transplantation (BMT). Kekoma¨ki et al 36 evaluated the outcome of kidney transplantation in 166 patients receiving a graft from not fully HLA-matched cadaveric donors. Five HPA-5a homozygous recipients were regrafted with kidneys from HPA-5b-positive donors. Four of them (80%), who were all typed as HLA-A3,B7, developed an acute vascular rejection. Contrarily, only one of the 32 patients (3%), who received HPA-5-matched graft, developed an acute vascular rejection.
Juji et al 37 reported on the clinical success rate of unrelated BMT in 715 HLA -A, -B, -C and -DR compatible donor-recipient (D/R) pairs. They found that the HPA-5 disparity only led to a decreased survival of recipients carrying the haplotype HLA-A*2402, B*5201 but not to an increased probability of GVHD.
Balduini et al 38 observed a group of 70 patients who received grafts from HLA-identical donors, of which 37 were HLA-identical siblings. Since the incidence of GVHD was increased in HPA-3-mismatched patients, they consider the antigen HPA-3 a possible mHA. Since the protein GPIIb that carries the HPA-3 epitopes has only been detected on platelets and not on other cells, it can hardly be involved in the GVHD.
Modelling of in vitro experiments by which HPA antigens could be identified as mHA in BMT is demanding and at the moment not within our reach. We therefore decided to perform a clinical study and assess the impact of HPA-1, -2, -3, -4 and -5 compatibility between donors and recipients on the incidence and severity of GVHD, relapse incidence, overall survival, dynamics of haematopoietic reconstitution, extent of transfusion therapy and some other parameters reflecting the recovery after BMT. The leading hypothesis was based on the assumption that HPA alloepitopes foreign to the graft could activate T-cell immune response and aggravate the GVHD or worsen the haematopoietic recovery, which would be reflected in impaired post-BMT parameters. To exclude the effect of MHC disparity, only HLA-identical sibling D/R pairs were entered into the collaborative study.
Patients and methods
In 223 cases of BMT, we observed the clinical effect of HPA disparity between patient and graft donor. To assemble the highest possible number of observations that would assure a critical statistical analysis, we initiated a collaborative study. Nine European transplantation centres contributed pretransplant DNA samples of patients and graft donors as well as the corresponding clinical data. All donors were HLA-A,B,DR-identical siblings, as typed locally according to the standards of European Federation of Immunogenetics (EFI). 39 From the starting 378 donor/recipient pairs, 155 had to be excluded from the study because of missing clinical data, poor quality of DNA or because the donor was not an HLA-identical sibling. The transplantations were performed between 1990 and 2000.
Of the final 223 patients, 122 were male and 101 female. The average age of the patients was 28.05 years. Of these, 159 were older and 63 younger than 16 years. We had no data regarding the age of one patient. The average age of donors was 28.47 years. All patients were Caucasian except three (one Chinese, one Indonesian and one African). The primary diagnoses of patients can be found in Table 1 .
All samples from the 223 D/R pairs were genotyped for HPA-1, -2, -3, -4 and -5 in our laboratory by the routine PCR-SSP method. 40 Gene frequencies of HPA-1, -2, -3, -4 and -5 were calculated with gene counting. The distribution of their HPA allele frequencies did not differ from the frequencies found in the European populations. 40 Considering the HPA matching, that is compatibility in the GVHD direction, the pairs were assembled into three groups: (1) HPA-1, -2, -3, -4 and -5 identical pairs; (2) HPA nonidentical but compatible pairs and (3) HPA incompatible pairs (n ¼ 92). Groups 1 and 2 were pooled and considered HPA compatible (n ¼ 127) (see Table 2 ). As expected, there were no disparities in HPA-4 antigens (all Are HPA minor histocompatibility antigens? P Rožman et al D/R pairs were HPA-4a homozygous) so HPA-4 was ruled out from the study. The distribution of single and multiple HPA incompatibilities between the donors and recipients is given in Table 3 . By means of a questionnaire derived from the MEDABform as recommended by EBMT, 41, 42 the following parameters were monitored in all D/R pairs: (i) pretransplantation data (gender, age, diagnosis, ABO blood group, CMV status, data regarding therapy, status of disease at the BMT, consecutive number of transplants, period between the diagnosis and BMT, observation time, conditioning with chemotherapy and irradiation and the calculated risk); (ii) data regarding the transplant (donors age, ABO blood group, source of stem cells, quantity of cells infused, graft manipulation and GVHD prevention) and (iii) posttransplantation data (day of granulocyte, lymphocyte, erythrocyte and platelet engraftment, evidence of haemopoietic chimerism, complications after day 100, situation on day 100, evidence of acute and chronic GVHD, treatment of GVHD, relapse incidence, the cause and day of eventual death, evidence of secondary malignancy, transfusion independence at day 100, necessary transfusion treatment with RBCs and platelet concentrates). For all definitions of pretransplantation, transplantation-related and post-transplantational data as well as for the survival analysis, EBMT recommendations were followed. 43, 44 The statistical evaluation of pretransplant data confirmed that the two groups of patients receiving HPA compatible and incompatible grafts did not statistically differ in their general characteristics (P40.13; see Table 1 ).
All data obtained by the questionnaire were encoded, and univariate, bivariate and regression analyses were performed according to the recommendation of EBMT. 44 Univariate analysis was used to calculate the averages and differences in general characteristics of HPA-matched and -mismatched groups of patients and donors of BM. The differences in age, diagnosis-to-BMT-period and observation period were calculated using Student's t-test. The proportions of patients younger than 16 years, proportions of males and female patients and donors, proportions of diagnoses, therapies and state of the disease at the BMT, as well as of the consecutive number of transplantations and of calculated risks were calculated using the w 2 test. The significance of differences in the general characteristics between the matched and mismatched D/R pairs was calculated using Student's t-test (number cells in the graft) and the w 2 test (differences of proportions of ABO blood group mismatches, proportions of men having received female grafts, the source of haematopoietic stem cells, proportions of CMV-negative patients having received CMV-positive grafts and GVHD prophylaxis).
The differences between the HPA-1, -2, -3 and -5-matched and -mismatched groups of patients in the engraftment, haemopoietic chimerism, best result at day 100, complications after day 100 and transfusion independence at day 100 were calculated using the w 2 test. Comparisons of haematopoietic recovery data and necessary transfusions of RBC and platelets were calculated using the Student's t-test and Mann-Whitney's U test.
The impact of the HPA mismatches on the relapse incidence (RI), overall survival (OS) and on the GVHD occurrence was tested with the Cox regression method and the resulting survival curves were compared using the logrank test.
The difference in the incidence of acute and chronic GVHD in patients older and younger than 16 years was calculated using Student's t-test, whereas the effect of the cumulative number of the D/R HPA-mismatches on the incidence of acute GVHD (aGVHD) and chronic GVHD (cGVHD) was assessed using the w 2 test. All statistical calculations were performed using the statistical package Statistica (StatSoft, Inc., 1997, Tulsa, USA). It was chosen due to broad range of provided 
Results
Effect of D/R matching in HPA on the incidence of serious forms of GVHD (aGVHD II-IV or cGVHD)
aGVHD of a certain grade (I-IV) occurred in 84 out of 223 patients (37.7%). aGVHD of grade II-IV was observed in 54 patients (24.2%), grade III or IV was observed in 20 patients (9.0%). cGVHD occurred in 41 of 223 patients (18.4%), in 21 patients (9.4%) limited cGVHD was observed and in 20 patients (9.0%) extensive GVHD was observed.
When the patients were stratified into younger and older than 16 years, it became evident that the aGVHD occurred more often in the older group: six out of 63 younger patients experienced aGVHD grade II-IV, as compared to 48 out of 159 older patients, and this difference is significant (P ¼ 0.001). Similarly, cGVHD (limited or extensive) occurred more often in the older group of patients. It appeared in six out of 63 younger patients, as compared to 35 out of 159 older patients. This difference is significant as well (P ¼ 0.016). Table 4 shows that 19 out of 29 patients (65.5%) who received HPA-1-mismatched bone marrow, experienced a serious form of the GVHD. Similarly, among 194 patients having received HPA-1-matched BM, 116 have experienced GVHD (59.8%). This difference is not statistically significant (P ¼ 0.23). Analysis of mismatches in HPA-2, -3 and -5 gave similar results, showing no significant difference in the GVHD incidence between the matched/ mismatched paired groups. Even after stratification of the patients into groups younger and older than 16 years, no significant differences were obtained (data not shown).
When the cumulative effect of single (n ¼ 64), double (n ¼ 24) and triple (n ¼ 4) HPA mismatches on the incidence of aGVHD and cGVHD was analysed, no significant differences were observed between the HPAmismatched and HPA-compatible groups (P40.58, data not shown).
Effect of the HPA matching on haematopoietic recovery and the clinical outcome of BMT When comparing the parameters related to the posttransplant period in Table 5 , none of the individual HPA-1, -2, -3 and -5 mismatches correlates either with the engraftment, haematopoietic chimerism, dynamics of neutrophil, leukocyte and platelet recovery, or with the clinical outcome of the transplantation as evaluated at day 100 (best result, complications after day 100, transfusion independence). On average, matched and mismatched groups demanded the same amount of blood components during the whole post-transplant period (see Table 5 ).
Effect of D/R matching in HPA on relapse incidence after BMT
There are no statistically significant differences in the occurrence of relapse between HPA-1, -2, -3 and -5 matched/mismatched groups of patients. There was also no difference if the patients were stratified according to age into younger and older than 16 years (63 and 159, respectively, data not shown), see Table 6 .
Effect of D/R matching in HPA on overall survival after BMT
We observed no significant differences in overall survival between the paired groups, who received HPA-1, -2, -3 and -5 compatible or mismatched transplants (see Table 7 ). The result was similar if the cumulative number of mismatches was considered or if the mismatched patients were stratified according to age (younger vs older than 16 years; data not shown).
Discussion
We are aware of many genetic factors that influence the encounter with allogenic blood forming tissue. Incompatibility of major and minor histocompatibility antigens between the patient and the graft donor is considered the main initiator of the GVHD. Should HPA be enrolled as minor transplantation antigens? Would the effect of HPA disparity be detected in D/R pairs who are HLA-identical siblings?
We performed a retrospective investigation to test the probability of HPA mismatching as an additional risk factor to be considered in the intrafamilial donor selection. Focusing on the expected GVHD, the HPA incompatibilities (mismatches) were established in the graft-versus-host Table 4 Effect of D/R matching in HPA on the incidence of serious forms of GVHD (aGVHD II-IV or cGVHD) after BMT from HLA-identical sibling (n=223)
HPA antigens
No. of D/R pairs GVHD Proportion of patients without GVHD Log-rank P Are HPA minor histocompatibility antigens? P Rožman et al We found no differences in the occurrence of aGVHD or cGVHD, regardless of whether a single HPA-1, -2, -3 and -5 locus incompatibility or the cumulative effect was analysed. This leads us to the conclusion that HPA-1, -2, -3 and -5 allopeptides should be ruled out as targets of effector immunological mechanisms involved in the development of GVHD and therefore not to be considered as minor transplantation antigens in clinical BMT.
However, in older patients both aGVHD and cGVHD occurred much more frequently than in younger patients. This corresponds to the observations of several other authors. 2, 3, 45, 46 Appropriate sampling is the crucial factor affecting the results of any investigation involving biologic diversity. Our preliminary analysis included only 170 D-R pairs and indicated a weak correlation between the incidence of GVHD and HPA-5 incompatibility in patients younger than 16 years. This conclusion was found deceptive when the number of observations was increased to the final number of 223 D/R pairs.
Since our results derive from two statistically comparable groups of HLA-identical D/R sibling pairs, they do not support reports published by Kekoma¨ki et al 36 and Balduini et al, 38 suggesting that HPA-5 and HPA-3 are minor transplantation antigens in kidney and BMT. Kekoma¨ki et al identified the antigen HPA-5b as the target of the acute alloimmune response in kidney transplantation. To question the relevance of HPA-5b in BMT settings, we analysed our results and observed that only six (35%) out of 17 HPA-5b-positive patients who have received HPA-5a-homogenous grafts developed a serious form of GVHD. On the other hand, the latter was registered in all (100%) of the three HPA-5a-positive recipients who received HPA-5b homozygous grafts. However, the number of observations does not allow a serious conclusion on the issue.
Analysis of the overall survival, relapse incidence and other parameters in our patient population shows that the HPA-1,-2,-3 and -5 matching did not affect the parameters of clinical recovery after BMT. No differences were observed in the overall survival and relapse incidence among paired groups even when stratification into patients older and younger than 16 years was performed. These results do not support the findings of Juji et al 47 stating that HPA-5a/b mismatch decreases disease-free survival in unrelated BMT.
Since the parameters of haematopoietic recovery in the HPA-1, -2, -3 and -5-compatible/incompatible groups are not statistically different, it seems that the homing of the transplanted haematopoietic stem cells is not hindered by surrounding expressing foreign HPA epitopes; an observation that coincides with the general opinion that platelet glycoproteins do not act as factors influencing the homing of haematopoietic stem cells. 29 The interpretation of results obtained by our investigation demands critical consideration. We must keep in mind that the net effect of many mechanisms operating in opposite directions has been registered and statistically n.e. On the other hand, a graft-versus-leukaemia effect, ascribed to minor transplantation antigens, could prolong the disease-free period in certain leukaemic patients. [48] [49] [50] It may well be that the hierarchy of responsiveness to different HPA allotypes is restricted by certain HLA allotypes or haplotypes. As mentioned earlier, Kekoma¨ki et al found the haplotype HLA A3,B7 in four of five patients who received an HPA-5-incompatible graft and developed an acute vascular rejection. 36 The immunologic situation in kidney transplantation can hardly be compared with the situation in BMT. However, the specific restriction in peptide presentation by HLA molecules should be the same regardless of the target tissue. None of our HPA-5-incompatible D/R pairs carry the haplotype HLA A3,B7. Most surprising is our observation that the haplotype HLA A3,B7 was found in seven out of 54 (12.9%) of our patients with an aGVHD and in six out of 41 (14.6%) patients with a cGVHD not taking account of the HPA compatibility with the donor. The frequency of this haplotype appears to be elevated when compared to the frequency of HLA A3,B7 in our group without any history of GVHD where it was found in eight out of 103 patients (7.8%), or to the frequency in European population with 4.4% as published by Gjertson and Lee. 51 Calculating the statistical association is not appropriate since the ethnic structure of both groups is not matched. One could easily hypothesise that under both circumstances the immunological rejection can be put down to a common denominator, a mismatched minor histocompatibility antigen other than HPA.
Considering all arguments mentioned above, we feel free to conclude that compatibility of HPA antigens between donors and recipients can be neglected as a possible risk factor in clinical BMT. 
